No Data
Hong Kong stocks movement | Pharmaceutical stocks plummeted across the board as Trump announced that he will mandate a price reduction for Pharmaceutical in the USA, disrupting the existing drug pricing system.
Pharmaceutical stocks have all plummeted; as of the time of this report, KEYMED BIO-B (02162) fell 5.83% to HKD 39.6; REMEGEN (09995) fell 4.81% to HKD 35.65; INNOCARE (09969) fell 4.35% to HKD 9.23; INNOVENT BIO (01801) fell 4.01% to HKD 50.3.
INNOCARE (09969.HK) will release its Earnings Reports on May 13.
$INNOCARE (09969.HK) will release its Earnings Reports on May 13, and investors are encouraged to pay attention. How were the previous results? Q1 2024 revenue was 0.166 billion yuan, net income was -0.146 billion yuan, and EPS was -0.08 yuan. Futubull reminds: 1. There are no hard rules for the accounting year division for Hong Kong and US listed companies; it is entirely decided by the company itself, so each earnings report period can serve as the cutoff date for the company’s annual report, rather than being based on the calendar year. 2. Generally, the company will hold an earnings report meeting on or around the release date mentioned above, with company management present.
INNOCARE's BCL2 inhibitors are expected to be included in breakthrough therapeutic varieties.
InnoCare Pharma to Review Q1 2025 Financial Results
INNOCARE (09969.HK) will hold a Board of Directors meeting on May 13 to approve the first quarter performance.
Glory Exchange, on April 28, announced that INNOCARE (09969.HK) will hold a Board of Directors meeting on May 13, 2025, to consider and approve the unaudited first quarter results of the company and its subsidiaries for the three months ending March 31, 2025, and its release.
INNOCARE: DATE OF BOARD MEETING
